Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Goodwill (2016 - 2022)

Aytu Biopharma (AYTU) has disclosed Goodwill for 7 consecutive years, with $8.6 million as the latest value for Q1 2022.

  • Quarterly Goodwill fell 77.1% to $8.6 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Mar 2022, down 77.1% year-over-year, with the annual reading at $65.8 million for FY2021, 134.25% up from the prior year.
  • Goodwill for Q1 2022 was $8.6 million at Aytu Biopharma, down from $46.3 million in the prior quarter.
  • The five-year high for Goodwill was $65.8 million in Q2 2021, with the low at $8.6 million in Q1 2022.
  • Average Goodwill over 4 years is $32.9 million, with a median of $28.1 million recorded in 2020.
  • The sharpest move saw Goodwill soared 134.25% in 2021, then plummeted 77.1% in 2022.
  • Over 4 years, Goodwill stood at $15.4 million in 2019, then soared by 82.56% to $28.1 million in 2020, then surged by 65.0% to $46.3 million in 2021, then plummeted by 81.37% to $8.6 million in 2022.
  • According to Business Quant data, Goodwill over the past three periods came in at $8.6 million, $46.3 million, and $46.3 million for Q1 2022, Q4 2021, and Q3 2021 respectively.